A Phase 1 Study of BPI-371153 in Subjects With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD)
and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in
patients with advanced solid tumors or relapsed/refractory lymphoma.